

Multiple Myeloma Update From the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting



References

Boccardo M, Cavallo F, Gay FM, et al. PANORAMA 2: Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients. . 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8509.

San-Miguel JF, Weisel KC, Moreau P, et al. PANORAMA 2: Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8510.

Martinez-Lopez J, Garcia-Sanz R, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease (MRDO) detection in multiple myeloma. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8511.

Lokhorst HM, Plesner T, Gimsing P, et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8512.

Touzeau C, Kolb B, Hulin C, et al. Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of phase (Ph) I/II trial. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8513.

Kumar S, Bensinger W, Zimmerman TM, et al. Weekly MLN9708, and investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8514.

Palumbo A, Brinchen S, Rajkumar, V, et al. Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8517.

Weisel KC, Dimopoulos MA, Moreau P, et al. Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8514.

Goldschmidt H, Dimopoulos MA, Weisel KC, et al. Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8528.

Multiple Myeloma Update From the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting

Wang M, Martin T, Bensinger W, et al. Final results form the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8529

Leleu A, Touzeau C, Benboubker L, et al. Phase Ib dose escalation study of oral quisinostat, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8530

Alsina M, Richardson PGG, Schlossman RL, et al. Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8531

Jagannath S, Hofmeister CC, Bas RC, et al. Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients(Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8532

Nooka AK, Langston AA, Waller EK, et al. Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8540

Pandey S, Rajkumar SV, Dispenzieri A, et al. Beneficial effect of complete response and type of therapy in multiple myeloma. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8541

Lonial S, Jagannath S, Moreau P, et al. Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8542

Jakubowiak AJ, Dytfeld D, Griffith KA, et al. Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8543

Catalano JV, Palumbo A, Weisel KC, et al. Lenalidomide (LEN)-melphalan-prednisone induction followed by LEN maintenance (MPR-R) in newly diagnosed multiple myeloma (NDMM) elderly patients (Pts) with moderate renal impairment (RI): MM-015 trial post-hoc analysis. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8544

Multiple Myeloma Update From the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting



Al-Hamadani M, Go RS, Use of stem cell transplantation (SCT) as initial therapy in multiple myeloma (MM) and impact of sociodemographic factors in the era of novel agents: Analysis of 137,409 patients using the National Cancer Data Base (NCDB). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8580

Song KW, Dimopoulos MA, Weisel KC, et al. Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM 1 LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8583

Richardson PGG, Hofmeister CC, Siegel DSD, et al. MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8584

Matous J, Siegel DSD, Duong HK, et al. MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8585

Siegel DSD, Richardson PGG, Vij R, et al. Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8588

Alahamdi MS, Tay J, Early versus late treatment for smoldering (asymptomatic) multiple myeloma: A systematic review. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8593

Atrash S, Tullos A, Panozzo S, et al. Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8595

Hilger JD, Berenson JR, Klein LM, et al. A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8598

Berenson JR, Hilger JD, Dichmann R, et al. Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM). 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8599

Takamatsu H, Murata R, Zheng J, et al. A comparison between next-generation sequencing and ASO-qPCR for minimal residual disease detection in multiple myeloma. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8601

Multiple Myeloma Update From the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting



Kassim A, McDuffie JS, Mosse CA et al. Minimal residual disease (MRD) status pre- and post- high-dose therapy/autologous stem (HDC/ASCT) cell transplantation for multiple myeloma (MM) in the era of novel agents. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8605

Ghimire KB, Rajkumar V, Dispenzieri A, et al. Implications of rapidity of response to initial therapy in multiple myeloma. 2013 American Society of Clinical Oncology Annual Meeting:Abstract 8606

Lee HC, Shah JJ, Orlowski RZ Novel Approaches to Treatment of Double-Refractory Multiple Myeloma ASCO.org/edbook. 2013;e302(e306)

Reece, D Update on the Initial Therapy of Multiple Myeloma ASCO.org/edbook. 2013;e307(e312)

San-Miguel JF, Paiva B, Gutierrez NC New Tools for Diagnosis and Monitoring of Multiple Myeloma ASCO.org/edbook. 2013;e313(e318)